Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert De Meerleer

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
BJU International|November 10, 2022
Post-prostatectomy radiotherapy: does late toxicity lead the game?Gert De Meerleer
International Journal of Radiation Oncology, Biology, Physics|September 22, 2023
How High Should We Go for Para-aortic Lymph Node Radiation Therapy?Julia Murray, Gert De Meerleer
International Journal of Radiation Oncology, Biology, Physics|May 15, 2022
Postoperative Radiation Therapy in Prostate Cancer: Timing, Duration of Hormonal Treatment and the Use of PSMA PET-CTCharlien Berghen, Gert De Meerleer
The Lancet. Oncology|March 20, 2025
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boostingGert De Meerleer, Kato Rans
European Urology|June 12, 2010
Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30Piet Ost, Alberto Bossi, Gert De Meerleer
European Urology|April 30, 2019
Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?Gaëtan Devos, Gert De Meerleer, Steven Joniau
The Journal of Urology|August 10, 2022
Editorial CommentAlberto Bossi, Gustave Roussy, Gert De Meerleer
European Urology|September 17, 2011
Intensity-modulated radiotherapy: the gold standard for postprostatectomy irradiation?Alberto Bossi, Gert De Meerleer, Piet Ost
Arab Journal of Urology|August 23, 2016
Oligometastatic prostate cancer: Metastases-directed therapy?Hein Van Poppel, Gert De Meerleer, Steven Joniau
European Urology Oncology|May 31, 2022
Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate CancerGert De Meerleer, Kato Rans, Steven Joniau, et al.
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
BJU International|November 10, 2022
Post-prostatectomy radiotherapy: does late toxicity lead the game?Gert De Meerleer
International Journal of Radiation Oncology, Biology, Physics|September 22, 2023
How High Should We Go for Para-aortic Lymph Node Radiation Therapy?Julia Murray, Gert De Meerleer
International Journal of Radiation Oncology, Biology, Physics|May 15, 2022
Postoperative Radiation Therapy in Prostate Cancer: Timing, Duration of Hormonal Treatment and the Use of PSMA PET-CTCharlien Berghen, Gert De Meerleer
The Lancet. Oncology|March 20, 2025
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boostingGert De Meerleer, Kato Rans
European Urology|June 12, 2010
Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30Piet Ost, Alberto Bossi, Gert De Meerleer
European Urology|April 30, 2019
Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?Gaëtan Devos, Gert De Meerleer, Steven Joniau
The Journal of Urology|August 10, 2022
Editorial CommentAlberto Bossi, Gustave Roussy, Gert De Meerleer
European Urology|September 17, 2011
Intensity-modulated radiotherapy: the gold standard for postprostatectomy irradiation?Alberto Bossi, Gert De Meerleer, Piet Ost
Arab Journal of Urology|August 23, 2016
Oligometastatic prostate cancer: Metastases-directed therapy?Hein Van Poppel, Gert De Meerleer, Steven Joniau
European Urology Oncology|May 31, 2022
Another Step Towards the Acceptance of Metastasis-directed Therapy in Low-volume Metastatic Prostate CancerGert De Meerleer, Kato Rans, Steven Joniau, et al.
Pageof 18